RecruitingPhase 1Phase 2NCT07374419

Atamparib in Patients With Advanced Solid Tumors

A Phase Ib/II Study of Atamparib in Patients With Advanced Solid Tumors

Sponsor

Nerviano Medical Sciences (Shanghai) Ltd.

Enrollment

178 participants

Start Date

Mar 18, 2026

Study Type

INTERVENTIONAL

Conditions

Solid Tumor NSCLC Adenocarcinoma

Summary

This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called atamparib RP2D and a drug called atamparib escalation levels for people with nsclc adenocarcinoma and solid tumor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGatamparib escalation levels

Bid, Oral, escalating at different dose levels

DRUGatamparib RP2D

Bid, oral, RP2D

Locations(1)

Unit 3.53, 3rd Floor, No. 5, Lane 720 Cailun Road, Pilot Free Trade Zone, Shanghai, P.R.China

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07374419

Related Trials

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT0538255966 locations

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

NCT074893781 location

Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool.

NCT052451361 location

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT0419876642 locations

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

NCT061607524 locations